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Abstract
Following a request from the European Commission, the Panel on Additives and Products or
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientiﬁc opinion on L-tryptophan
produced by fermentation with a genetically modiﬁed strain of Escherichia coli CGMCC 7.248 when
used as a nutritional additive in feed and water for drinking for all animal species and categories. The
production strain E. coli CGMCC 7.248 and its recombinant DNA were not detected in the ﬁnal product.
The product L-tryptophan, manufactured by fermentation with E. coli CGMCC 7.248, does not give rise
to any safety concern with regard to the genetic modiﬁcation of the production strain. L-Tryptophan
produced by E. coli CGMCC 7.248 is safe for non-ruminant target species. The use of unprotected
L-tryptophan in ruminant feed should be avoided. L-Tryptophan produced by fermentation by E. coli
CGMCC 7.248 is safe for the consumer. The level of endotoxins present in the product and its dusting
potential indicate an inhalation risk for the user. L-Tryptophan produced by E. coli CGMCC 7.248 is not
a skin or eye irritant but it is a dermal sensitiser. The use of L-tryptophan produced by E. coli CGMCC
7.248 in animal nutrition does not pose a risk to the environment. The product under assessment is
regarded as an effective source of the amino acid L-tryptophan for all non-ruminant species. For the
supplemental L-tryptophan to be as efﬁcacious in ruminants as in non-ruminant species, it requires
protection against degradation in the rumen.
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1. Introduction
1.1. Background and Terms of Reference
Regulation (EC) No 1831/20031 establishes the rules governing the Community authorisation of
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an
application in accordance with Article 7.
The European Commission received a request from Andres Pintaluba, S.A.2 for authorisation of the
product Feed Grade L-tryptophan (L-tryptophan), produced by fermentation with Escherichia coli
CGMCC 7.248 when used as a feed additive for all animal species (category: nutritional additives;
functional group: amino acids, salts and analogues).
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the
application to the European Food Safety Authority (EFSA) as an application under Article 4(1)
(authorisation of a feed additive or new use of a feed additive). The particulars and documents in
support of the application were considered valid by EFSA as of 19 July 2017.
According to Article 8 of Regulation (EC) No 1831/2003, EFSA, after verifying the particulars and
documents submitted by the applicant, shall undertake an assessment in order to determine whether
the feed additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on
the safety for the target animals, consumer, user and the environment and on the efﬁcacy of the
product Feed Grade L-tryptophan (L-tryptophan) produced by a strain of E. coli CGMCC 7.248, when
used under the proposed conditions of use (see Section 3.1.4).
1.2. Additional information
L-Tryptophan (minimum content of 98% on dry matter basis) produced by fermentation with six
strains of E. coli (KCCM 11132P, DSM 25084, FERM BP-11200, FERM BP-11354, CGMCC 7.59 or CGMCC
3667) is currently authorised for use as a nutritional additive for all animal species.3 The product under
assessment, L-tryptophan (minimum 98%) produced by a genetically modiﬁed strain of E. coli CGMCC
7.248, has not been previously authorised as a feed additive in the European Union (EU).
L-Tryptophan is authorised for use in food,4 cosmetics5 and as a veterinary medicinal product.6,7
L-Tryptophan is described in the European Pharmacopoeia (2017), monograph 01/2017:1272.
The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) published
nine opinions on the safety and efﬁcacy of L-tryptophan produced by different strains of E. coli for all
animal species (EFSA FEEDAP Panel, 2013, 2014a,b, 2015a,b, 2016a,b, 2017a,b).
The Panel on Dietetic Products, Nutrition and Allergies (NDA) of EFSA issued a scientiﬁc opinion on
the substantiation of health claims related to L-tryptophan (EFSA NDA Panel, 2011). The Panel on
Nutrition, Dietetic Products, Novel Food and Allergy of the Norwegian Scientiﬁc Committee for Food
Safety (VKM) published an opinion on histidine, methionine, S-adenosylmethionine and tryptophan
added to foods and drinks and in food supplements (VKM, 2013) and another on L-tryptophan in food
supplements and energy drinks (VKM, 2016).
1 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use in
animal nutrition. OJ L 268, 18.10.2003, p. 29.
2 Andres Pintaluba S.A., Prudenci Bertrana 5, 43206 Reus, Spain. Representing Henan Julong Biological Engineering Co., Ltd.
3 Commission Implementing Regulation (EU) 2017/873 of 22 May 2017 concerning the authorisation of L-tryptophan produced
by Escherichia coli as a feed additive for all animal species, OJ L 134, 22.5.2017, p. 14.
4 Regulation (EU) No 609/2013 of the European Parliament and of the Council of 12 June 2013 on food intended for infants and
young children, food for special medical purposes, and total diet replacement for weight control and repealing Council Directive
92/52/EEC, Commission Directives 96/8/EC, 1999/21/EC, 2006/125/EC and 2006/141/EC, Directive 2009/39/EC of the
European Parliament and of the Council and Commission Regulations (EC) No 41/2009 and (EC) No 953/2009, OJ L 181,
29.6.2013, p. 35.
5 Commission Decision of 9 February 2006 amending Decision 96/335/EC establishing an inventory and a common nomenclature
of ingredients employed in cosmetic products. OJ L 97, 5.4.2006, pp. 1–528.
6 Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classiﬁcation
regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1.
7 Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community
procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin,
repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the
Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council. OL L 152, 16.6.2009, p. 11.
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2. Data and methodologies
2.1. Data
The present assessment is based on data submitted by the applicant in the form of a technical
dossier8 in support of the authorisation request for the use of L-tryptophan produced by fermentation
with E. coli CGMCC 7.248 as a feed additive.
The FEEDAP Panel used the data provided by the applicant together with data from other sources,
such as previous risk assessments by EFSA or other expert bodies, peer-reviewed scientiﬁc papers, and
other scientiﬁc reports, to deliver the present output.
EFSA has veriﬁed the European Union Reference Laboratory (EURL) report as it relates to the
methods used for the control of L-tryptophan produced by E. coli CGMCC 7.248 in animal feed. The
Executive Summary of the EURL report can be found in Annex A.9
2.2. Methodologies
The approach followed by the FEEDAP Panel to assess the safety and the efﬁcacy of Feed Grade L-
tryptophan is in line with the principles laid down in Regulation (EC) No 429/200810 and the relevant
guidance documents: Guidance on nutritional additives (EFSA FEEDAP Panel, 2012a), Technical
guidance: Tolerance and efﬁcacy studies in target animals (EFSA FEEDAP Panel, 2011), Technical
Guidance for assessing the safety of feed additives for the environment (EFSA, 2008), Guidance for
establishing the safety of additives for the consumer (EFSA FEEDAP Panel, 2012b), Guidance on
studies concerning the safety of use of the additive for users/workers (EFSA FEEDAP Panel, 2012c),
Guidance on the assessment of bacterial susceptibility to antimicrobials of human and veterinary
importance (EFSA FEEDAP Panel, 2012d) and Guidance on the risk assessment of genetically modiﬁed
microorganisms and their products intended for food and feed use (EFSA GMO Panel, 2011).
3. Assessment
The subject of the present assessment is L-tryptophan (minimum 98%) produced by fermentation
with a genetically modiﬁed strain of E. coli (CGMCC 7.248). It is intended to be used as nutritional
additive (functional group amino acids, salts and analogues) in feed for all animal species and
categories.
3.1. Characterisation
3.1.1. Characterisation of the production organism
The additive is produced by a genetically modiﬁed strain of E. coli, which is deposited in the China
General Microbiological Culture Collection Center (CGMCC) with deposition number CGMCC 7.248.11 A
bioinformatic analysis of the whole genome sequence (WGS) of the production strain conﬁrmed the
identity of the production strain as an E. coli K-12 (MG1655) derivative
E. coli CGMCC 7.248 was tested for antibiotic susceptibility using broth microdilution using the
battery of antibiotics tested that EFSA recommended (EFSA FEEDAP Panel, 2012d) for E. coli. All
minimum inhibitory concentration values were below the corresponding cut-off values deﬁned by the
FEEDAP Panel.13
8 FEED dossier reference: FAD-2017-0019.
9 The full report is available on the EURL website: https://ec.europa.eu/jrc/sites/jrcsh/files/ﬁnrep_fad-2017-0019_tryptophan.pdf
10 Commission Regulation (EC) No 429/2008 of 25 April 2008 on detailed rules for the implementation of Regulation (EC) No
1831/2003 of the European Parliament and of the Council as regards the preparation and the presentation of applications and
the assessment and the authorisation of feed additives. OJ L 133, 22.5.2008, p. 1.
11 Technical dossier/Section II/Annex_II_2_1a.
13 Technical dossier/Section II/Annex_II_2_1c.
L-Tryptophan produced with Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 5 EFSA Journal 2019;17(2):5601
3.1.1.1. Characteristics of the recipient or parental microorganism
The recipient strain is E. coli K-12 MG1655. E. coli K-12 MG1655 is well-characterised and its safety
(non-pathogenicity) has been documented (Gorbach, 1978). The strain was shown to be ineffective in
colonising the human gut (Smith, 1975). Its genome has been fully sequenced (Blattner et al., 1997;
Hayashi et al., 2006).
3.1.1.2. Characteristics of the donor organism
3.1.1.3. Description of the genetic modiﬁcation process
The production strain CGMCC 7.248 was subsequently obtained by
No added antimicrobial resistance genes were found
in the genome of the production strain.
3.1.2. Manufacturing process
3.1.3. Characterisation of the additive
L-Tryptophan (International Union of Pure and Applied Chemistry (IUPAC) name: (2S)-2-amino-3-
(1H-indol-3-yl) propanoic acid; synonyms: (S)-a-amino-1-H-indole-3-propanoic acid, l-a-aminoindole-3-
propionic acid,-l-a-amino-3-indolepropionic acid, 2-amino-3-indolylpropanoic acid, l-b-3-indolylalanine)
has the Chemical Abstracts Service (CAS) No 73-22-3 and European Inventory of Existing Commercial
Chemical Substances (EINECS) No 200-795-6. The chemical formula is C11H12N2O2, the molecular
weight is 204.23 g/mol. The structural formula is given in Figure 1.
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The L-tryptophan content of the product is speciﬁed as ≥ 98% on ‘as is’ basis, the other
components being water (≤ 0.5%), crude ash (≤ 0.5%) and other amino acids (e.g. phenylalanine or
leucine, ≤ 1%).16 The analysis of ﬁve batches of L-tryptophan showed an average content of
tryptophan of 98.8% on dry matter basis (range 98.3–99.7%), water 0.1%, ash 0.2%17 and other
amino acids as tyrosine or phenylalanine were below the limit of detection (LOD) or up to 0.031%
phenylalanine (in only one batch).18 On a dry matter basis, the amount of identiﬁed material is on
average 99.0% (98.5–99.9%).
The speciﬁc optical rotation of ﬁve batches of the ﬁnal product was on average–30.5° (range –29.1
to –31.7°),19 which is within the range described in the European Pharmacopoeia (–30 to –33°) for this
amino acid and conﬁrms the identity of the L-enantiomer.20
3.1.3.1. Impurities
Three batches of the ﬁnal product were analysed for heavy metals (lead, cadmium and mercury)
and arsenic. Lead, cadmium and arsenic were below the LOD, and mercury ranged from LOD to
0.013 mg/kg.21 Fluorine measured in three batches was < 10 mg/kg in all of them.22
Analysis of microbial contamination of the ﬁnal product (three batches) indicated that Salmonella
spp. (in 25-g samples) was absent; total aerobic bacterial count ranged from 5.5 9 102 to
2.2 9 103 CFU/g; aerobic spore formers ranged from 7.2 9 102 to 1.9 9 103 CFU/g and anaerobic
spore formers from < 4 to 1.4 9 102 CFU/g; E. coli, Staphylococcus coagulase positive, Clostridium
perfringens, sulﬁte-reducing bacteria, thermotolerant coliforms, total coliforms, faecal streptococci and
Enterobacteriaceae were < 10 CFU/g; and yeast and ﬁlamentous fungi were < 102 CFU/g.23
Aﬂatoxins B1, B2, G1 and G2, ochratoxin A, zearalenone, T2 and HT-2 toxins, fumonisins B1 and B2
and deoxynivalenol had concentrations below the limit of quantiﬁcation (LOQ) in three batches.24
Dioxins (polychlorinated dibenzodioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs)) and
dioxin-like polychlorinated biphenyls (DL-PCBs) were analysed in three batches of the ﬁnal product.
The sum of dioxins and DL-PCBs (WHO-PCDD/F-PCB-TEQ) ranged from 0.15 to 0.34 ng/kg
L-tryptophan on dry matter basis.25 Non-DL-PCBs were analysed in two batches and total of the six
PCBs were 1,200 ng/kg on dry matter basis in both batches.
The endotoxin activity (three batches analysed by Limulus amoebocyte lysate test) ranged from
0.82 to 2.03 IU/mg.26
1,10-Ethylidene-bis-L-tryptophan (EBT) and 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic
acid (MTCA), present in a speciﬁc brand of L-tryptophan produced by fermentation, were implicated in
the eosinophilia–myalgia syndrome outbreak that occurred in humans in New Mexico in 1989
(Hertzman et al., 1990). The concentrations of EBT and MTCA were analysed in three batches of the
ﬁnal product. EBT concentrations were < 10 mg/kg in all cases and MTCA was not detected.27 The
Figure 1: Structural formula of L-tryptophan
16 Technical dossier/Section II/Annex II.1.3a.
17 Technical dossier/Section II/Annex II.1.3b and Supplementary information November 2018/Annex II.1.3d. L-tryptophan
analysed by method ISO 13904:2016.
18 Technical dossier/Section II/Annex II.1.3c. Analysis performed by HPLC and LOD in % was 0.02.
19 Technical dossier/Section II/Annex II.1.3b.
20 European Pharmacopoeia 9th edition (2019), monograph 1/2015:1272.
21 Technical dossier/Section II/Annex II.1.4e and supplementary information November 2018/Annex II.1.4g. LOD in mg/kg were
0.01 for mercury and arsenic, 0.02 for lead and 0.5 for cadmium.
22 Technical dossier/Section II/Annex II.1.4c.
23 Technical dossier/Section II/Annex II.1.4a.
24 Technical dossier/Section II/Annex II.1.4a. LOQ (in µg/kg) was 2 for aﬂatoxins, ochratoxin A and T-2 toxin; 10 for zearalenone
and fumonisins B1 and B2; and 20 for HT-2 toxin and deoxynivalenol.
25 Technical dossier/Section II/Annex II.1.4c and II.1.4d.
26 Technical dossier/Section II/Annex II.1.4b.
27 Technical dossier/Section II/Annexes II.1.4a and II.1.4b and supplementary information November 2018/Annex II.1.4f. EBT
and MTC were analysed by HPLC DAD.
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maximum permitted content of EBT in L-tryptophan, as speciﬁed by the European Pharmacopoeia
(2017), is 10 mg/kg.
No viable cells of the production strain were found in three batches of the concentrate of the ﬁnal
product (each tested in triplicate). Tests were done by incubating a 1% solution of 0.2 g of product in
non-selective medium for 24 and 48 h at 37°C and plating 0.2 mL of these cultures on selective solid
medium and incubating the plates at 30°C for 2 days.28
The absence of recombinant DNA of the production strain was conﬁrmed in three samples of 1 g of
the ﬁnal product tested in triplicate
Overall, the data on undesirable contaminants (chemical and microbiological) as well as on
tryptophan impurities do not give rise to safety concerns.
3.1.3.2. Physical characteristics
The product under assessment is a white or slightly yellow crystalline powder with slight odour.
Tapped density ranged from 380 to 390 kg/m3 and bulk density from 200 to 210 kg/m3.23 It is
sparingly soluble in water. The pH measured in ﬁve batches ranged from 5.9 to 6.3.19
The particle size distribution (three batches analysed by laser diffraction) showed that the
percentages of particles having a diameter below 100, 50 and 10 lm were 98%, 69% and 15% (v/v),
respectively.30 The dusting potential (three batches analysed by the Stauber–Heubach method) ranged
from 0.77 to 0.96 g/m3.31
3.1.3.3. Stability and homogeneity
The shelf-life of the additive (three batches, commercial packaging consisting in polyethylene bags,
protected from light) was tested at 25°C and at 40°C for 29 and 6 months, respectively.32 No losses
were observed at 25°C after 29 months and up to 1% at 40°C after 6 months.
The stability of three batches in three different vitamin–mineral premixtures: one for piglets,
another for chickens for fattening (both without choline chloride) and a third one for pregnant sows
(containing 50,000 mg choline chloride/kg) at a supplementation rate of 0.51% were tested at 25°C
for 6 months. The premixtures were packed as described above. The losses observed after the
6-month period were 2.6%, 0% and 9% in premixtures for piglets, chickens for fattening and sows,
respectively.33
Stability in complete feeds was tested in three batches of complete feeds for piglets (based on
barley, soybean meal, whey, maize and fat), for chicken for fattening (based on maize and soybean
meal) or for pregnant sows (based on maize, sunﬂower and beet pulp) at a supplementation rate of
0.06% tryptophan, after storage at 25°C for 3 months. Mash and pelleted feed were tested. The
packaging was the one described above. The pelleting temperatures were ~ 60°C, ~ 50°C and ~ 60°C
and the pelleting process induced a loss of 11%, 4% or 1% of the supplemented additive,
respectively. For piglets feed, after the 3-month period, the observed losses were of 12% and 7% in
mash feed and in pelleted feed, respectively.34 For chicken for fattening feed, the observed loss in
mash feed was 11% and there was no loss in pelleted feed. For pregnant sows feed, no losses were
observed in mash or in pelleted feed.
The capacity of the additive to distribute homogeneously in the premixture described above was
studied by analysing 10 subsamples. The coefﬁcient of variation (CV) was 4.1%.35
The capacity of the additive to distribute homogeneously in the complete feed for piglets described
above was studied analysing 10 subsamples, both of mash and pelleted feed. The CVs were 1.0% and
1.4%, respectively.36
28 Technical dossier/Section II/Annex II.2.1c.
30 Technical dossier/Section II/Annex II.1.5c.
31 Technical dossier/Section II/Annex II.1.5a.
32 Technical dossier/Section II/Annexes II.4.1a and II.4.1b.
33 Technical dossier/Section II/Table II.23 and Annexes II.4.1d and II.4.1e and supplementary information November 2018/
Annexes II.4.1k, II.4.1m and II.4.1o.
34 Technical dossier/Section II/Annexes II.4.1f and II.4.1g and supplementary information November 2018/Annexes II.4.1q and
II.4.1s.
35 Technical dossier/Section II/Annex II.4.1d and II.4.2b.
36 Technical dossier/Section II/Annex II.4.1f and II.4.2c.
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3.1.3.4. Physicochemical incompatibilities
No physico-chemical incompatibilities in feed are expected with other additives, medicinal products
or feed materials.
3.1.4. Conditions of use
It is proposed that L-tryptophan will be used in feeds to achieve an adequate amino acid proﬁle and
to meet the L-tryptophan requirements for all animal species. It can be added directly to feedingstuffs.
No inclusion levels have been proposed, as the requirements, in quantitative terms, depend on the
species, the physiological state of the animal, the performance level, the environmental conditions and
the amino acid composition of the unsupplemented diet.
3.2. Safety
3.2.1. Safety aspects of the genetic modiﬁcation
The recipient organism E. coli K-12 MG1655 is considered to be safe. The production strain CGMCC
7.248 Those
traits do not raise any safety concern. No added antimicrobial resistance genes were found in the
genome of the production strain.
The applicant provided sufﬁcient information that neither the production strain nor its recombinant
DNA are present in the ﬁnal product. The product L-tryptophan, manufactured by fermentation with
E. coli CGMCC 7.248, does not give rise to any safety concern with regard to the genetic modiﬁcation
of the production strain.
3.2.2. Safety for the target species
Tolerance studies are not normally required for highly puriﬁed amino acids. Such tolerance studies
with a certain indispensable amino acid will inevitably result in amino acid imbalances, with depression
of feed intake and hence impaired performance and increased nitrogen excretion. This is also the case
for the product under application which contains 98.8% tryptophan and ≤ 1% unidentiﬁed material on
a dry matter basis. The endotoxin activity ranged from 0.82 to 2.03 IU/mg. These values are
compared with ca 1,000 IU/mg commonly found in feedingstuffs (Cort et al., 1990). Therefore, at the
usual conditions of use of the additive in feed, the endotoxins added by the additive would be
insigniﬁcant compared to the background in feed. Therefore, the FEEDAP Panel considers that safety
concerns for target species are unlikely to arise from this product. Since no particular safety concerns
arose from the E. coli CGMCC 7.248, the FEEDAP Panel conﬁrms the safety for the target species of
L-tryptophan produced by this strain.
The L-tryptophan requirements of the target animal species and the safety of the use of this
essential amino acid in non-ruminant and ruminant nutrition were summarised in previous opinions of
the EFSA FEEDAP Panel (2013, 2015a).
Given the high purity of the product, the FEEDAP Panel considers that the use of L-tryptophan
produced with E. coli CGMCC 7.248 is safe for non-ruminant target species when used to supplement
the diet in appropriate amounts. The FEEDAP Panel reiterates that ruminal metabolism of unprotected
L-tryptophan may result in the production of toxic quantities of 3-methylindole (skatole), which causes
pulmonary disease (fog fever; emphysema) in cattle and goats (Hammond et al., 1978). Consequently,
only a protected form of L-tryptophan should be used in ruminants.
3.2.2.1. Conclusions on safety for the target species
The use of L-tryptophan produced using E. coli CGMCC 7.248 in supplementing feed to compensate
for tryptophan deﬁciency in feedingstuffs is safe for non-ruminant target species. The use of
unprotected L-tryptophan in ruminant feed poses safety concerns.
3.2.3. Safety for the consumer
The absorption and metabolic fate of L-tryptophan were described in a previous opinion (EFSA
FEEDAP Panel, 2013).
The amino acid L-tryptophan, supplemented to feed, will be incorporated into proteins of tissues
and/or products of animal origin and any of their potential excess will be metabolised and excreted as
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urea/uric acid and carbon dioxide. Therefore, the composition of tissues and products of animal origin
will not be affected by the use of L-tryptophan in animal nutrition.
The product under assessment is produced by fermentation. Concerns for the consumer would
derive not from the amino acid itself, which will be incorporated into proteins, but from possible
residues from fermentation. Considering that (1) the product originating from E. coli CGMCC 7.248 is
highly puriﬁed (98.8% L-tryptophan and < 1% unidentiﬁed material on a dry matter basis) and (2) the
concentrations of EBT and MTCA are < 10 mg/kg additive or below LOD, respectively, no additional
toxicological data are required.
3.2.3.1. Conclusions on safety for the consumer
L-Tryptophan product produced by fermentation with E. coli CGMCC 7.248 presents no concern to
consumers of animal products.
3.2.4. Safety for the user
The applicant provided an acute inhalation toxicity study, dermal and eye irritation studies and a
skin sensitisation study performed with the L-tryptophan produced by E. coli CGMCC 7.248.37
3.2.4.1. Effects on the respiratory system:
`Practically all particles have a diameter < 100 lm and the dusting potential is up to 1 g/m3 (see
Section 3.1.3).
In an acute inhalation toxicity study performed in accordance with the Organisation for Economic
Co-operation and Development (OECD) Guideline 436,38 the mass median aerodynamic diameter
(MMAD) of the test item (98.1% on dry matter by potentiometric method) was found too large
(approx. 28.4 lm with 14% of particles < 4 lm) for the generation trials. As the proper atmosphere to
conduct the test could not be established, the FEEDAP Panel cannot conclude on the potential acute
inhalation toxicity of the additive under assessment.
The effects of endotoxin inhalation and the exposure limits have been described in a previous
opinion (EFSA FEEDAP Panel, 2015a). The scenario used to estimate the exposure of persons handling
the additive to endotoxins in the dust, based on the EFSA Guidance on user safety (EFSA FEEDAP
Panel, 2012c) is described in the Appendix A. The health-based recommended threshold for the
quantity of inhaled endotoxins per working day is 900 IU, derived from provisional occupational
exposure limits given by the Dutch Expert Committee on Occupational Safety (DECOS) (Health Council
of the Netherlands, 2010) and the UK Health and Safety Executive (HSE, 2013). Based upon the
calculation of the potential endotoxin content in dust, the inhalation exposure could be up to 1,083
endotoxin IU per working day, indicating thus an inhalation exposure to endotoxins for persons
handling the additive.
3.2.4.2. Effects on skin and eyes
In an acute dermal irritation study in accordance with OECD Guideline 404, 0.5 g of the product
under assessment was applied on the skin of three rabbits for 4 h.39 No lesions were observed and the
additive is considered not irritant for the skin.
In an eye irritation study in accordance with OECD 405, 0.1 g of the test item was introduced in
the conjunctival sac of the eye of three female New Zealand white rabbits and surveyed up to 72 h
post-instillation.40 No ocular changes were observed at 48 and 72 h. The product is considered not
irritant for the eye.
In a skin sensitisation study (Magnusson and Kligman maximisation test) in accordance with OECD
Guideline 406, the test item caused sensitisation reaction (discrete or patchy erythema) in 30% of the
animals (allergenicity grade III). Consequently, the additive should be considered as a skin sensitiser.41
3.2.4.3. Conclusions on safety for the user
The level of endotoxins present in the product and its dusting potential indicate an inhalation risk
for the user. The additive is not a skin and eye irritant but it is a skin sensitiser.
37 Technical dossier/Supplementary information November 2018/2 tryptophan reply/Reply to question 12.
38 Technical dossier/Seciton III/Annex III.3a.
39 Technical dossier/Section III/Annex III.3c.
40 Technical dossier/Section III/Annex III.3b.
41 Technical dossier/Section III/Annex III.3d.
L-Tryptophan produced with Escherichia coli for all animal species
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2019;17(2):5601
3.2.5. Safety for the environment
The production strain E. coli CGMCC 7.248 and its recombinant DNA were not detected in the ﬁnal
product. The product does not pose any environmental safety concern associated with the genetic
modiﬁcation of the production strain. L-Tryptophan produced using E. coli CGMCC 7.248 is safe for the
environment.
The amino acid L-tryptophan is a physiological and natural component of the proteins of living
organisms. When given to animals, it is not excreted as such, but as urea/uric acid, indole-related
compounds and carbon dioxide. The use of the product L-tryptophan in animal nutrition would not lead
to any localised increase in the concentration in the environment.
The use of L-tryptophan produced by E. coli CGMCC 7.248 in animal nutrition does not pose a risk
to the environment.
3.3. Efﬁcacy
Efﬁcacy studies are not required for amino acids naturally occurring in the proteins of plants and
animals. The nutritional role of L-tryptophan is well established in the scientiﬁc literature. The additive
feed grade L-tryptophan is regarded as an effective source of the amino acid L-tryptophan.
Overdosing of supplemental L-tryptophan may increase skatole and indole in the hind gut resulting
in boar taint of pork (Zamaratskaia and Squires, 2008).
The efﬁcacy of this essential amino acid in non-ruminant and ruminant nutrition was summarised in
a previous opinion of the EFSA FEEDAP Panel (2014b). Supplemental L-tryptophan is degraded by
ruminal microbiota if not given in a protected form.
3.4. Post-market monitoring
The FEEDAP Panel considers that there is no need for speciﬁc requirements for a post-market
monitoring plan other than those established in the Feed Hygiene Regulation42 and Good
Manufacturing Practice.
4. Conclusions
The production strain E. coli CGMCC 7.248 and its recombinant DNA were not detected in the ﬁnal
product. The product L-tryptophan, manufactured by fermentation with E. coli CGMCC 7.248, does not
give rise to any safety concern with regard to the genetic modiﬁcation of the production strain.
The use of L-tryptophan produced by E. coli CGMCC 7.248 is safe for non-ruminant target species.
The use of unprotected L-tryptophan in ruminant feed poses safety concerns.
As L-tryptophan produced by fermentation by E. coli CGMCC 7.248 is highly pure (≥ 98.8% on dry
matter basis) and because neither the amino acid L-tryptophan nor its metabolites accumulate in
animal tissues/products, and the concentrations of EBT and MTCA are low (< 10 mg/kg additive each),
this product presents no concern to consumers of animal products.
The level of endotoxins present in the product and its dusting potential indicate an inhalation risk
for the user. L-Tryptophan produced by E. coli CGMCC 7.248 is not a skin or eye irritant but it is a
dermal sensitiser.
The use of L-tryptophan produced by E. coli CGMCC 7.248 in animal nutrition does not pose a risk
to the environment.
The product under assessment is regarded as an effective source of the amino acid L-tryptophan for
all non-ruminant species. For the supplemental L-tryptophan to be as efﬁcacious in ruminants as in
non-ruminant species, it requires protection against degradation in the rumen.
5. Recommendations
It is recommended that speciﬁcation of the additive complies with the European Pharmacopeia with
regards L-tryptophan related impurities such as 1,10-ethylidene-bis- L-tryptophan (EBT) < 10 mg/kg
(European Pharmacopoeia, 2017).
42 Regulation (EC) No 183/2005 of the European Parliament and of the Council of 12 January 2005 laying down requirements for
feed hygiene. OJ L 35, 8.2.2005, p. 1.
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Documentation provided to EFSA
1) Feed grade L-tryptophan produced with Escherichia coli CGMCC 7.248. 2017. Submitted by
Andres Pintaluba S.A.
2) Feed grade L-tryptophan produced with Escherichia coli CGMCC 7.248. Supplementary
information. November 2018. Submitted by Andres Pintaluba S.A.
3) Evaluation report of the European Union Reference Laboratory for Feed Additives on the
Methods of Analysis for L-tryptophan produced by Escherichia coli CGMCC 7.248.
4) Comments from Member States.
Chronology
Date Event
31/3/2017 Dossier received by EFSA
7/6/2017 Reception mandate from the European Commission
19/7/2017 Application validated by EFSA – Start of the scientiﬁc assessment
19/10/2017 Request of supplementary information to the applicant in line with Article 8(1)(2) of Regulation
(EC) No 1831/2003 – Scientiﬁc assessment suspended. Issues: manufacturing process,
characterisation of the additive and of the production microorganism, stability and safety for the
user
19/10/2017 Comments received from Member States
17/11/2017 Reception of the Evaluation report of the European Union Reference Laboratory for Feed Additives
26/11/2018 Reception of supplementary information from the applicant - Scientiﬁc assessment re-started
22/1/2019 Opinion adopted by the FEEDAP Panel. End of the Scientiﬁc assessment
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CAS Chemical Abstracts Service
CFU colony forming unit
CGMCC China General Microbiological Culture Collection Center
CV coefﬁcient of variation
DL-PCB dioxin-like polychlorinated biphenyls
DECOS Dutch Expert Committee on Occupational Safety
DM dry matter
EBT 1,10-ethylidene-bis-L-tryptophan
EINECS European Inventory of Existing Commercial Chemical Substances
EURL European Union Reference Laboratory
FCC Food Chemical Codex
FD ﬂuorescence detection
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed
GMO EFSA Panel on Genetically Modiﬁed Organisms
HPLC-DAD high-performance liquid chromatography with diode array detection
HSE Health and Safety Executive
IUPAC International Union of Pure and Applied Chemistry
LOD limit of detection
LOQ limit of quantiﬁcation
MMAD mass median aerodynamic diameter
MTCA 1-methyl-1,2,3,4-tetrahydro-beta-carboline-3-carboxylic acid
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
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PCDD polychlorinated dibenzodioxin
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VKM Norwegian Scientiﬁc Committee for Food Safety
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Appendix A – Calculation of exposure to endotoxins
Calculation of maximum acceptable levels of exposure from feed additives
The probable exposure time according to EFSA guidance (EFSA FEEDAP Panel, 2012c) for additives
added in premixtures assumes a maximum of 40 periods of exposure per day, each comprising
20 s = 40 9 20 = 800 s/day. With an uncertainty factor of 2, maximum inhalation exposure would
occur for 2 9 800 = 1,600 s = 0.444 h/day. Again, assuming a respiration volume of 1.25 m3/h, the
inhalation volume providing exposure to potentially endotoxin-containing dust would be
0.444 9 1.25 = 0.556 m3/day. This volume should contain no more than 900 IU endotoxin, so the
dust formed from the product should contain no more than 900/0.556 = 1,619 IU/m3.
Calculation of endotoxin content of dust
Two key measurements are required to evaluate the potential respiratory hazard associated with the
endotoxin content of the product (the dusting potential of the product, expressed in g/m3, and the
endotoxin activity of the dust, determined by the Limulus amoebocyte lysate assay (expressed in IU/g)).
If data for the dust are not available, the content of endotoxins of the product can be taken instead. If the
content of endotoxins of the relevant additive is a IU/g and the dusting potential is b g/m3, then the
content of endotoxins of the dust, c IU/m3, is obtained by simple multiplication, a 9 b. This resulting
value is further used for calculation of the potential inhalatory exposure of users to endotoxins from the
additive under assessment (Table A.1) (EFSA FEEDAP Panel, 2012c).
Table A.1: Estimation of user exposure to endotoxins from the additive L-tryptophan produced by
Escherichia coli CGMCC 7.248, including consideration of using a ﬁlter mask FF P2 or FF
P3 as a preventative measure
Calculation Identiﬁer Description Amount Source
a Endotoxin content IU/g product 2,030 Technical dossier
b Dusting potential (g/m3) 0.96 Technical dossier
a 9 b c Endotoxin content in the air (IU/m3) 1,949
d No of premixture batches made/working
day
40 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012c)
e Time of exposure (s) per production of one
batch
20 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012c)
d 9 e f Total duration of daily exposure/worker (s) 800
g Uncertainty factor 2 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012c)
f 9 g h Reﬁned total duration of daily exposure/
worker (s)
1,600
h/3,600 i Reﬁned total duration of daily exposure (h) 0.44
j Inhaled air (m3) per eight-hour working
day
10 EFSA Guidance on user safety
(EFSA FEEDAP Panel, 2012c)
j/8 9 i k Inhaled air during exposure (m3) 0.56
c 9 k l Endotoxin inhaled (IU) during
exposure per eight-hour working day
1,083
m Health-based recommended exposure limit
of endotoxin (IU/m3) per eight-hour
working day
90 Health Council of the
Netherlands (2010)
m 9 j n Health-based recommended exposure
limit of total endotoxin exposure (IU)
per eight-hour working day
900
l/10 Endotoxins inhaled (IU) per eight-hour
working day reduced by ﬁlter mask FF P2
(reduction factor 10)
108
l/20 Endotoxins inhaled (IU) per eight-hour
working day reduced by ﬁlter mask FF P3
(reduction factor 20)
54
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Annex A – Executive Summary of the Evaluation Report of the European
Union Reference Laboratory for Feed Additives on the Method(s) of
Analysis for L-tryptophan produced by Escherichia coli CGMCC 7.248
In the current application, authorisation is sought under Article 4(1) for L-tryptophan produced by
Escherichia coli CGMCC 7.248, under the category/functional group 3(c) ‘nutritional additives’/‘amino
acids, their salts and analogues’, according to Annex I of Regulation (EC) No 1831/2003. Authorisation
is sought for all animal species. L-Tryptophan is already authorised as a feed additive under
Commission Directive 88/485/EEC.
For the quantiﬁcation of L-tryptophan in the feed additive, the Applicant validated and further veriﬁed
the method based on titration described in the European Pharmacopoeia monograph 01/2017:1272. For
the quantiﬁcation of L-tryptophan in premixtures and feedingstuffs, the Applicant submitted two single-
laboratory validated and further veriﬁed analytical methods based on high-performance liquid
chromatography with diode array detection (HPLC-DAD).
However, the EURL previously evaluated (i) the ring-trial validated Community method based on
HPLC coupled with ﬂuorescence detection (FD) for the quantiﬁcation of L-tryptophan in feedingstuffs;
and (ii) the ring-trial validated EN ISO 13904:2016 method ‘Animal feeding stuffs – Determination of
tryptophan content’ for the quantiﬁcation of L-tryptophan in feed additive and premixtures (containing
more than 2% of tryptophan). Based on the performance characteristics available, the EURL
recommends for ofﬁcial control these two ring-trial validated methods to quantify tryptophan in the
feed additive, premixtures and/or feedingstuffs. In addition, the EURL identiﬁed the ‘L-tryptophan
monograph’ of the Food Chemical Codex (FCC) for the identiﬁcation of the feed additive.
Further testing or validation of the methods to be performed through the consortium of National
Reference Laboratories as speciﬁed by Article 10 (Commission Regulation (EC) No 378/2005, as last
amended by Regulation (EU) 2015/1761) is not considered necessary.
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